|Bid||24.85 x 800|
|Ask||28.65 x 800|
|Day's Range||28.41 - 29.98|
|52 Week Range||16.13 - 32.34|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 09, 2015|
|1y Target Est||N/A|
CryoLife (CRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Joining me from CryoLife's management team are Pat Mackin, CEO; and Ashley Lee, CFO. Comments made on this call that look forward in time involve risks and uncertainties that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
CryoLife (CRY) delivered earnings and revenue surprises of 27.27% and 15.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?